Pijnenburg, M. W. http://orcid.org/0000-0003-0902-0860
Rubak, S. http://orcid.org/0000-0001-7010-2350
Skjerven, H. O.
Verhulst, S.
Elenius, V. http://orcid.org/0000-0001-9264-9904
Hugen, C. http://orcid.org/0000-0002-9449-9679
Jauhola, O.
Kempeneers, C.
Melén, E.
Reier Nilsen, T. http://orcid.org/0000-0001-8184-0607
Rutjes, N. W. http://orcid.org/0000-0002-3996-1963
Ruotsalainen, M.
Schaballie, H.
Zwitserloot, A. M.
Proesmans, M.
Mäkelä, M. J. http://orcid.org/0000-0002-2933-3111
Funding for this research was provided by:
Sanofi
University of Helsinki
University of Helsinki
Article History
Received: 2 January 2024
Accepted: 13 March 2024
First Online: 27 March 2024
Declarations
:
: According to the Finnish Medical Research Act (488/1999) available at ExternalRef removed, ethics committee approval for this study was unnecessary. All participants gave their informed consent to participate in stakeholder interviews or the Delphi, with all contributions anonymised.
: All participants consented to their views' publication.
: V Elenius has received lecture and/or advisory board fees from Glaxo, Novartis, Sanofi, Vertex Pharmaceuticals outside the present study. C Hugen has no competing interest to declare outside the present study. O Jauhola has received lecture and/or advisory fees from Airsonett and Astra Zeneca outside the present study. C Kempeneers has received research grant and travel funding from GSK, outside the submitted work. MJ Mika has no competing interest to declare outside the present study. E Melén has received lecture and/or advisory board fees from Airsonett, ALK, AstraZeneca, Chiesi and Sanofi outside the present study. HO Skjerven is participating in MSD and Boehringer Ingelheim studies, and has received advisory board fees from Boehringer Ingelheim and Sanofi outside the present study. M Pijnenburg is involved in a DMC of Novartis, is participating in studies of AstraZeneca and Sanofi and received advisory board fees from Sanofi outside the present study. M Proesmans has no competing interest to declare outside the present study. T Reier-Nilsen has received fees for lectures, advisory boards or consultant work from ALK, MediTuner and Sanofi outside the present study. S Rubak has no competing interest to declare outside the present study. M Ruotsalainen has no competing interest to declare outside the present study. NW Rutjes has received advisory board fees from GlaxoSmithKline and Sanofi, outside the submitted work. H Schaballie has received advisory board fees from Pfizer and Sanofi, outside the submitted work. S Verhulst has no competing interest to declare outside the present study. AM Zwitserloot reports a research grant (money to institution) from Vertex Pharmaceuticals, outside the submitted work.